Medmain Inc., a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has raised 3.3 million USD through a third-party allotment of shares, with One Capital as the lead investor and Niremia Collective and Plug and Play as additional participants. With this round, the company’s total equity funding has reached 18 million USD.
Medmain Inc. is a Japanese medtech startup with the corporate mission “To create a world where medical services can be accessed with technology anywhere, anytime”. As a partner to medical professionals around the world, the company develops and provides PidPort, an AI-powered cloud system that supports digital pathology.
Medmain has been providing a full range of services in the field of digital pathology, starting with a digitization service for specimen slides, to remote diagnosis support that connects remote facilities via cloud computing, to the presentation of high accuracy and rapid analysis of pathology results using AI, all of which are utilized at many facilities. We have also succeeded in accelerating the speed of development of pathology AI, our core technology, by creating a proprietary platform that accelerates AI development by means of transfer learning.
Also Read: Veeva Announces Veeva AI, an AI Agent for Life Sciences
Purpose and Background of the Fundraising (Challenges Medmain Aims to Address)
The funds raised will be used to further enhance the development of our product “PidPort,” invest in infrastructure for digitalization, strengthen our sales organization, apply for regulatory approval of our pathology AI, and build a foundation for international expansion.
With the global increase in cancer diagnoses, the number of pathology examinations has also risen significantly, leading to a chronic shortage of personnel and placing a heavy workload on medical institutions. Traditionally, pathology diagnoses have long relied on physical glass slides, but at Medmain, we have been supporting medical institutions through the provision of digital services and our platform, “PidPort.”
PidPort is currently used by many clients in a wide range of settings, including remote diagnostic support and consultations between medical institutions, multi-facility conferences, academic conferences, educational use in lectures and training sessions, as well as research and quality control at universities and corporations.
Moving forward, we will continue to enhance functionality and strengthen integration with surrounding systems to further improve service convenience. At the same time, we are committed to expanding support and value delivery to more medical sites, and to strengthening our organizational structure in preparation for global expansion.
SOURCE: PRNewsWire